GCN2iB is primarily researched for its potential in cancer therapy. It functions as an inhibitor of GCN2, a kinase involved in the integrated stress response (ISR) pathway. By blocking GCN2, this compound can disrupt the stress response mechanisms in cancer cells, making them more susceptible to treatments like chemotherapy or immunotherapy. Its application is particularly promising in tumors that rely on the ISR pathway for survival under nutrient-deprived conditions, such as those found in the tumor microenvironment. Additionally, GCN2iB is being explored for its role in enhancing the efficacy of immune checkpoint inhibitors, potentially improving outcomes in cancer immunotherapy. Research is ongoing to further understand its therapeutic potential and optimize its use in clinical settings.